35 results about "Valvular heart disease" patented technology

A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

The invention discloses a capsule for treating senile calcific valvular heart disease and a preparation method thereof, so as to solve the problem of cardiac valve calcification is difficult to treat. The preparation method is characterized by comprising the following steps: (1) distilling tetrapanax papyriferum, fruit of rosa davurica pall and littleflower stringbush bark and root through water vapor to extract volatile oil for standby, and storing the decoction dregs for standby; (2) crushing gecko and coked rice sprout into fine powder for standby; (3) uniformly mixing persimmon bark, sunglow, poncirus bark, horsetail, filipendula palmata (pall) maxim, fiveleaf akebia fruit and nakedflower beautyberry branchlet and leaf with the decoction dregs obtained in the step 1, extracting the mixture with alcohol for twice, mixing the two alcohol extracting solutions, filtering, recycling ethanol, and concentrating the filtrate to extract at reduced pressure; (4) adding the fine powder obtained in the step 2 in the extract obtained in the step 3, mixing evenly, drying the mixture at 60 DEG C, crushing the mixture into fine powder, adding polysorbate-80 in the mixture to prepare granules, drying, trimming the granules, spraying the volatile oil obtained in the step 1, mixing evenly, and filling a capsule with the mixture to obtain the capsule. Clinical experiments prove that the capsule for treating senile calcific valvular heart disease disclosed by the invention has the advantages of good curative effect and high safety, so that the capsule is worthy of clinical application and popularization.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.